| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Eldred Kary is a Director at GALT. Recent filings cover 12 purchases and 0 sales. Those positions are worth an estimated $226K at current prices.
Our model assigns Eldred Kary a strong insider score of 81/100, based on 8 past trades. Over a 12-month horizon, 85.7% of those trades were profitable, with an average 12-month return of +47.9%.
Eldred Kary's largest disclosed position is in GALT as Director, worth about $226K. Net of sales, the recent Form 4 record there shows accumulation of 26,200 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 31, 2019 | GALT Galectin Therapeutics Inc | Director | Buy | 3,033 | $4.28 | $12,981.24 | +7.3% | |
| Sep 25, 2018 | GALT Galectin Therapeutics Inc | Director | Buy | 2,000 | $6.10 | $12,199.80 | +5.1% |